Organogenesis Holdings (STU:2PQ) Piotroski F-Score: 5 (As of Jun. 28, 2026) — Near Median


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.12
GF Value €2.74
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Piotroski F-Score?

Organogenesis Holdings STU:2PQ 67 Piotroski F-Score is 5 as of Jun. 28, 2026, which is at its 10-year median of 5.00. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.74 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 981 Drug Manufacturers companies, Organogenesis Holdings ranks better than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organogenesis Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Organogenesis Holdings's Piotroski F-Score or its related term are showing as below:

STU:2PQ' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 5

During the past 11 years, the highest Piotroski F-Score of Organogenesis Holdings was 8. The lowest was 1. And the median was 5.

Organogenesis Holdings  (STU:2PQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Organogenesis Holdings Piotroski F-Score Related Terms


Organogenesis Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Piotroski F-Score Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 4.00 8.00 3.00

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 4.00 6.00 3.00 5.00

STU:2PQ vs SIGA, ELTP, TKNO: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Piotroski F-Score falls into.


STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -8.143 + 18.375 + 37.32 + -45.98 = €1.6 Mil.
Cash Flow from Operations was -28.501 + 2.623 + 33.665 + 18.275 = €26.1 Mil.
Revenue was 87.375 + 128.215 + 192.211 + 31.356 = €439.2 Mil.
Gross Profit was 63.42 + 97.329 + 149.581 + 9.063 = €319.4 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(432.339 + 399.798 + 434.373 + 511.315 + 449.793) / 5 = €445.5236 Mil.
Total Assets at the begining of this year (Mar25) was €432.3 Mil.
Long-Term Debt & Capital Lease Obligation was €52.9 Mil.
Total Current Assets was €232.3 Mil.
Total Current Liabilities was €65.8 Mil.
Net Income was -15.833 + 11.11 + 7.328 + -17.43 = €-14.8 Mil.

Revenue was 120.987 + 103.774 + 120.956 + 80.191 = €425.9 Mil.
Gross Profit was 93.862 + 79.631 + 91.303 + 58.247 = €323.0 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(421.803 + 411.698 + 402.113 + 475.481 + 432.339) / 5 = €428.6868 Mil.
Total Assets at the begining of last year (Mar24) was €421.8 Mil.
Long-Term Debt & Capital Lease Obligation was €30.9 Mil.
Total Current Assets was €248.0 Mil.
Total Current Liabilities was €60.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organogenesis Holdings's current Net Income (TTM) was 1.6. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Organogenesis Holdings's current Cash Flow from Operations (TTM) was 26.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1.572/432.339
=0.00363604

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-14.825/421.803
=-0.03514674

Organogenesis Holdings's return on assets of this year was 0.00363604. Organogenesis Holdings's return on assets of last year was -0.03514674. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Organogenesis Holdings's current Net Income (TTM) was 1.6. Organogenesis Holdings's current Cash Flow from Operations (TTM) was 26.1. ==> 26.1 > 1.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=52.884/445.5236
=0.11870078

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=30.872/428.6868
=0.07201528

Organogenesis Holdings's gearing of this year was 0.11870078. Organogenesis Holdings's gearing of last year was 0.07201528. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=232.253/65.758
=3.53193528

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=248.048/60.174
=4.12217901

Organogenesis Holdings's current ratio of this year was 3.53193528. Organogenesis Holdings's current ratio of last year was 4.12217901. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Organogenesis Holdings's number of shares in issue this year was 127.797. Organogenesis Holdings's number of shares in issue last year was 126.296. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=319.393/439.157
=0.7272866

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=323.043/425.908
=0.7584807

Organogenesis Holdings's gross margin of this year was 0.7272866. Organogenesis Holdings's gross margin of last year was 0.7584807. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=439.157/432.339
=1.01577003

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=425.908/421.803
=1.00973203

Organogenesis Holdings's asset turnover of this year was 1.01577003. Organogenesis Holdings's asset turnover of last year was 1.00973203. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Organogenesis Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Organogenesis Holdings (STU:2PQ) has a Piotroski F-Score of 5 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Organogenesis Holdings and its competitors. This is near median its historical median of 5.00. Over the past decade, Organogenesis Holdings' Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, Organogenesis Holdings ranks #379 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Organogenesis Holdings' Piotroski F-Score too high?
Organogenesis Holdings' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Organogenesis Holdings' value of 5 is 0% at this industry median. Based on the distribution chart, Organogenesis Holdings ranks #379 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Piotroski F-Score compare to SIGA and ELTP?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #379 out of 981 companies for Piotroski F-Score. This puts Organogenesis Holdings in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Organogenesis Holdings' value of 5 is 0% at this benchmark. Historically, Organogenesis Holdings' own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Organogenesis Holdings has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.74, compared to a current price of €2.12 — trading 22.6% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Piotroski F-Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.12 is trading 22.6% below its estimated GF Value™ of €2.74. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: €2.74 vs. price of €2.12 (22.6% below fair value)
  • GF Score™: 67/100 with 5 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#379 of 981)

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.12
Price
€2.74
GF Value